Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Opto Circuits (India) Ltd (OPTOCIRCUI)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532391 NSE: OPTOCIRCUI Medical Equipment/Supplies/Accessories | Small Cap | Opto Circuits (I) Share Price
₹1.78 0.00 (0.00%)
As on 23-May'22 18:01
Opto Circuits (India) Ltd (OPTOCIRCUI)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532391 NSE: OPTOCIRCUI Medical Equipment/Supplies/Accessories | Small Cap | Opto Circuits (I) Share Price
₹1.78 0.00 (0.00%)
As on 23-May'22 18:01
Key Metrics
Valuation Multiples
Market Cap
₹54 Cr.
Current Price
₹1.8
52-Week Low / High
₹2 / 2
TTM EPS
₹-4.3
TTM Sales
₹106 Cr.
Book Value per Share
₹-7.7
P/E Ratio
0.00
Industry PE
127.5
Price to Book (P/B)
-0.23
Price to Sales (P/S)
0.50
EV/EBITDA
-149.39
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-344.88%
Return on Capital Employed (ROCE)
-103.79%
Return on Assets (ROA)
-85.11%
Operating Profit Margin
13.5%
Net Profit Margin
-761.35%
Gross Profit Margin
0.3%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-40.27%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-62.83%
Net Profit Growth (1 Year)
-
-2773.09%
Asset Quality
Promoter Holding
18.52%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹-531 Cr.
Equity
₹300.6 Cr.
Face Value
₹10
All Time Low / High
₹1.45 / 262.90
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Opto Circuits (India) Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 19.2% | 15% | 12.9% | 4.5% | -6.3% | 0.7% | -19.9% | 0.7% | 2.1% | -106.6% | - |
| Value Creation Index ⓘ | 0.4 | 0.1 | -0.1 | -0.7 | -1.5 | -1.0 | -2.4 | -1.0 | -0.9 | -8.6 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 603 | 670 | 699 | 263 | 146 | 76.7 | 50.4 | 63.5 | 105 | 62.6 | 0 |
| Sales YoY Gr. | - | 11% | 4.4% | -62.4% | -44.4% | -47.5% | -34.3% | 26% | 65.2% | -40.3% | - |
| Adj EPS ⓘ | 9.8 | 9.7 | 10 | 1.8 | -2.9 | -0.7 | -15 | 0.3 | 1.1 | -11.6 | -5.3 |
| YoY Gr. | - | -1.4% | 3.7% | -82.1% | -263.7% | NA | NA | NA | 220.6% | -1163.3% | - |
| BVPS (₹) ⓘ | 43.9 | 50.1 | 60 | 61.8 | 53 | 52.3 | 36.8 | 39.1 | 39.1 | 1.3 | -4 |
| Adj Net Profit ⓘ | 238 | 234 | 243 | 43.3 | -70.9 | -18 | -364 | 9.8 | 32.7 | -349 | -159 |
| Cash Flow from Ops. ⓘ | 118 | -29.5 | -92.9 | -15.7 | 55.7 | 335 | 57.4 | 46.6 | 42 | 21.3 | - |
| Debt/CF from Ops. ⓘ | 6.1 | -22.3 | -8.8 | -56 | 15.9 | 2.1 | 12.4 | 11.8 | 12.6 | 23 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -22.3% | -15.6% | 7.5% | -40.3% | ||||
| Adj EPS ⓘ | -201.9% | NA | NA | -1163.3% | ||||
| BVPSⓘ | -32.4% | -52.4% | -67.2% | -96.7% | ||||
| Share Price | -18% | -13.6% | - | - | ||||
Key Financial Parameters ⓘ
| Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 24.7 | 20.6 | 18.2 | 2.9 | -5.1 | -1.4 | -33.7 | 1 | 2.8 | -57.4 | 389.7 |
| Op. Profit Mgn % ⓘ | 40 | 41.7 | 39.4 | 43.7 | 36.5 | 30.6 | 29.8 | 31.8 | 39.8 | 26.9 | -4905.1 |
| Net Profit Mgn % ⓘ | 39.4 | 35 | 34.7 | 16.5 | -48.5 | -23.5 | -722.8 | 15.5 | 31.2 | -556.7 | -63493.1 |
| Debt to Equity ⓘ | 0.7 | 0.5 | 0.6 | 0.6 | 0.7 | 0.6 | 0.8 | 0.5 | 0.5 | 12.5 | - |
| Working Cap Days ⓘ | 375 | 609 | 906 | 2,774 | 4,958 | 8,646 | 10,239 | 6,471 | 3,949 | 4,624 | 62,800 |
| Cash Conv. Cycle ⓘ | 234 | 264 | 360 | 1,308 | 2,330 | 2,263 | 734 | 401 | 3 | -122 | -5,29,655 |
Valuation of Opto Circuits (I) - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,586.83 | 2,356.85 | 2,399.35 | 1,408.01 | 1,187.12 | 312.98 | 215.29 | 228.36 | 257.77 | 181.20 |
| Operating Expenses ⓘ + | 1,139.50 | 1,740.35 | 1,804.50 | 1,144.16 | 947.79 | 306.15 | 191.70 | 176.34 | 191.93 | 156.73 |
| Operating Profit ⓘ | 447.33 | 616.50 | 594.85 | 263.85 | 239.33 | 6.83 | 23.59 | 52.02 | 65.84 | 24.47 |
| Operating Profit Margin (%) | 28.2% | 26.2% | 24.8% | 18.7% | 20.2% | 2.2% | 11.0% | 22.8% | 25.5% | 13.5% |
| Other Income ⓘ + | 29.16 | 13.56 | 7.31 | 63.32 | 24.80 | 33.81 | 0.70 | 1.21 | 1.98 | 4.76 |
| Interest ⓘ | 32.06 | 59.20 | 109.24 | 137.14 | 143.51 | 43.66 | 17.07 | 5.76 | 3.24 | 28.78 |
| Depreciation ⓘ | 50.80 | 54.63 | 95.95 | 75.70 | 94.55 | 41.37 | 16.03 | 12.59 | 10.79 | 5.54 |
| Profit Before Tax ⓘ | 393.64 | 516.24 | 385.48 | 112.01 | -155.34 | -35.71 | -507.49 | 36.49 | 53.79 | -1,379.41 |
| Tax ⓘ | 25.09 | -57.16 | 3.12 | 21.97 | 1.71 | 1.15 | 0.81 | 0.90 | 2.19 | 0.17 |
| Profit After Tax | 368.55 | 573.40 | 382.36 | 90.04 | -157.05 | -36.86 | -508.30 | 35.59 | 51.61 | -1,379.58 |
| PAT Margin (%) | 23.2% | 24.3% | 15.9% | 6.4% | -13.2% | -11.8% | -236.0% | 15.6% | 20.0% | -761.0% |
| Adjusted EPS (₹) | 15.2 | 23.6 | 15.7 | 3.8 | -6.5 | -1.5 | -21.1 | 1.2 | 1.7 | -45.5 |
| Dividend Payout Ratio (%) | 22.80% | 12.70% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 1,366.86 | 1,699.33 | 2,081.93 | 2,228.80 | 1,952.38 | 1,688.31 | 853.98 | 942.59 | 1,159.77 | -76.04 | |
| Debt + | 892.13 | 1,061.33 | 1,320.43 | 1,368.71 | 1,372.48 | 1,095.33 | 965.05 | 835.78 | 807.53 | 987.32 | |
| Minority Interest | 21.89 | 18.04 | 20.59 | 19.64 | 19.03 | 18.19 | 13.26 | 11.89 | 12.13 | -9.97 | |
| Trade Payables | 228.80 | 206.72 | 408.42 | 274.34 | 265.73 | 169.66 | 39.87 | 30 | 51.80 | 114.36 | |
| Others Liabilities ⓘ | 489.99 | 487.67 | 437.68 | 401.75 | 570.93 | 240.82 | 313.47 | 189.05 | 112.09 | 83.06 | |
| Total Liabilities ⓘ | 2,999.68 | 3,473.09 | 4,269.04 | 4,293.24 | 4,180.56 | 3,212.30 | 2,185.63 | 2,009.31 | 2,143.32 | 1,098.73 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 1,067.57 | 1,160.18 | 1,167.64 | 1,108.95 | 955.71 | 352.63 | 356.26 | 342.93 | 656.30 | 351.67 | |
| CWIP ⓘ | 33.96 | 42.95 | 44.46 | 46.56 | 31.02 | 304.26 | 303.18 | 355.82 | 358.11 | 1.13 | |
| Investments ⓘ | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0 | |
| Inventories | 432.52 | 511.77 | 744.30 | 789.13 | 749.93 | 480.52 | 223.08 | 98.41 | 95.91 | 51.55 | |
| Trade Receivables | 678.42 | 846.57 | 1,589.40 | 1,727.10 | 1,842.72 | 357.39 | 242.17 | 37.67 | 58.77 | 55.77 | |
| Cash Equivalents | 234.18 | 174.31 | 43.17 | 20.15 | 26 | 9.56 | 8.40 | 11.16 | 4.40 | 3.04 | |
| Others Assets ⓘ | 553.01 | 737.30 | 680.06 | 601.34 | 575.18 | 1,707.94 | 1,052.53 | 1,163.30 | 969.81 | 635.58 | |
| Total Assets ⓘ | 2,999.68 | 3,473.09 | 4,269.04 | 4,293.24 | 4,180.56 | 3,212.30 | 2,185.63 | 2,009.31 | 2,143.32 | 1,098.73 | |
| PARTICULARS | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 130.62 | 126.68 | -140.07 | -0.12 | -145.41 | 724.16 | 308.52 | 69.58 | 45.17 | 72.27 |
| Cash Flow From Investing Activity ⓘ + | -596.17 | -337.30 | -102.08 | -10.81 | 83.26 | -8.66 | -118.39 | 3.86 | 17.19 | -149.52 |
| Cash Flow From Financing Activity ⓘ + | 577.40 | 150.74 | 111.02 | -12.09 | 68 | -731.94 | -191.13 | -70.68 | -69.12 | 75.89 |
| Net Cash Flow ⓘ | 111.85 | -59.87 | -131.14 | -23.02 | 5.85 | -16.44 | -1 | 2.76 | -6.76 | -1.37 |
| PARTICULARS | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 30.95 | 37.41 | 20.23 | 4.18 | -7.52 | -2.03 | -42.35 | 4.7 | 5.68 | N/A |
| ROCE (%) | 24.06 | 22.4 | 15.45 | 6.79 | -0.31 | 0.24 | -21.91 | 2.52 | 3.26 | N/A |
| Asset Turnover Ratio | 0.69 | 0.73 | 0.62 | 0.33 | 0.28 | 0.08 | 0.08 | 0.11 | 0.12 | 0.11 |
| PAT to CFO Conversion(x) | 0.35 | 0.22 | -0.37 | -0 | N/A | N/A | N/A | 1.96 | 0.88 | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 128.60 | 118.10 | 185.30 | 429.90 | 548.80 | 1,282.90 | 508.20 | 223.60 | 68.30 | 115.40 |
| Inventory Days | 75.20 | 73.10 | 95.50 | 198.80 | 236.60 | 717.50 | 596.40 | 256.90 | 137.60 | 148.50 |
| Payable Days | 84.70 | 65.60 | 97.10 | 180.50 | 186.90 | 704.50 | 449.40 | 138.50 | 132.60 | 434.30 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Opto Circuits (India) Ltd FAQs
The current trading price of Opto Circuits (I) on 23-May-2022 18:01 is ₹1.78.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-May-2022 the market cap of Opto Circuits (I) stood at ₹53.51 Cr
The latest P/E ratio of Opto Circuits (I) as of 22-May-2022 is 0.00.
The latest P/B ratio of Opto Circuits (I) as of 22-May-2022 is -0.44.
The 52-week high of Opto Circuits (I) is ₹1.94 and the 52-week low is ₹1.78.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Opto Circuits (I) is ₹0.25 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Opto Circuits (India) Ltd is a below average quality company.
The key valuation ratios of Opto Circuits (India) Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
No data found
About Opto Circuits (India) Ltd
Opto Circuits India (OCI), incorporated in the year 1992 is a multinational medical device company headquartered out of Bengaluru, India. The company designs, develop, manufacture, market and distribute a range of medical products that are used by healthcare establishments in more than 150 countries. The manufacturing is backed by a complete range of inspection and reliability testing equipments such as Bond Pull, Shear Testers, Stereo Microscopes, IR Viewers Spectrometers and many more.
OCI specialize in cardiac and vital signs monitoring, emergency cardiac care, vascular treatments and sensing technologies. Its products are US FDA listed and CE marked. Some of the well-known brands marketed by the company are Criticare Systems, Mediaid, Unetixs Vascular, Eurocor and Cardiac Science.
The company has customers in USA, Europe, Middle East, Far East, South Africa etc. To service these customers it has offices through its subsidiaries in USA, Germany, Singapore and Dubai. It has subsidiaries namely Mediaid Inc (USA), Eurocor Gmbh (Germany), Criticare Systems Inc (USA), Advanced Micronic Devices (India), Devon Innovations (India), ORMED Medical Technology (India) and Altron Industries (India).
It clients includes names like Manipal Groups of hospitals, Escorts Heart Hospital, Wockhardt Heart Hospitals, Apollo Group of Hospitals, Lilavati hospital, Breach Candy Hospital are among others.
In January 2009, the company’s California-based Mediaid Inc., the subsidiary company and the international marketing arm of the company had received Brazilian FDA agency - Agencia Nacional de Vigilancia Sanitaria (ANVISA) - approval for marketing and sale of the Mediaid brand of US FDA-approved Pulse Oximetry (SPO2) products (Patient Monitors & Sensors) in the country and surrounding geographies.
During December, 2010 Opto Circuits (India) has successfully acquired 76% of outstanding common stock of Cardiac Science Corporation US. The company plans to exercise its top-up option under the terms of the merger agreement. The merger is expected to occur in the next few days. Following the merger, Cardiac Science will become a wholly-owned subsidiary of Opto Circuits (India).
Products
Health Care products- Under this segment it manufactures Pulse Oximeters, Pulse Oximeter Sensors, Fluid warmers, Digital Thermometer,Cholesterol Monitors And Stent.
Opto Electronics products- The Company manufactures Infrared Emitters, Infra Red Detectors, Photo Sensor, Detector and Emitter Assemblies.
Recognition
The company has ISO 9001-2000 and ISO 13485-2003 quality system certification.
OCI has received 2 Star Trading House Status in accordance with the provisions of Exim Policy of Federal Government of India.
Opto Circuits (India) has been featured in Forbes Asia’s 200 ‘Best Under a Billion’ List, 2011 by Forbes magazine. This is the third time the company has made it to this list, the last two times being 2008 and 2009.
Milestones
2010
- Opto Circuits acquisition of Unetixs Vascular creates strong synergies for Criticare Systems.
- Opto Circuits Successfully Completes Acquisition of Cardiac Science.
- Opto Circuits forays into manufacturing of cardiac stents - acquires Kolkata based N.S. Remedies.
2011
- Opto Circuits presents Bangalore Metro Rail Corporation Ltd. it's first public access defibrillator.
- Opto Circuits launches campaign to promote heart safe environments on World Heart Day.
- Opto Circuits ranked amongst Forbes' Asia's 200 Best Under a Billion companies for third year.
2012
- Opto Circuits launches new Powerheart G5 AED.
- Opto Circuits Supplies AEDs to 2012 UEFA European Football Championship.
- Opto Circuits launches its first Sirolimus Drug Eluting Stent."
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
